Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological response modifiers.

R K Oldham

    Journal of the National Cancer Institute
    |May 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Biological response modifiers (BRM) are rapidly advancing cancer therapies. Their use alone or with other treatments promises greater understanding and specificity in cancer treatment this decade.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Growth of tumor-derived activated T cells for the treatment of advanced cancer.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    "Historical Vignettes".

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Cancer biotherapy: when, why and how long?

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Fundamentally different.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Treatment of drug resistance: biotherapy or chemotherapy?

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same journal

    Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

    Journal of the National Cancer Institute·2026
    Same journal

    Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

    Journal of the National Cancer Institute·2026
    Same journal

    A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

    Journal of the National Cancer Institute·2026
    Same journal

    Response to Yu, Wang and Ge.

    Journal of the National Cancer Institute·2026
    Same journal

    Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

    Journal of the National Cancer Institute·2026
    Same journal

    Welcome reduction of US cervical cancer rates despite state differences.

    Journal of the National Cancer Institute·2026
    See all related articles

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biotechnology

    Background:

    • The field of cancer therapy is experiencing rapid advancements.
    • New surgical techniques, radiation delivery methods, and radiosensitizers are emerging.
    • Development of novel chemotherapeutic agents and improved utilization of existing drugs are underway.

    Purpose of the Study:

    • To highlight the significant changes and future potential of biological response modifiers (BRM) in cancer treatment.
    • To emphasize the role of BRM in advancing cancer biology understanding and therapeutic specificity.
    • To discuss the impact of emerging technologies on cancer research and treatment development.

    Main Methods:

    • Review of current and developing cancer treatment modalities.

    Related Experiment Videos

  • Analysis of the integration of biological response modifiers (BRM) with conventional therapies.
  • Exploration of technological advancements including computers, cell fusion, and genetic engineering.

    • Main Results:

    • Biological response modifiers (BRM) represent a key area of change in cancer therapy.
    • BRM, used independently or in conjunction with other treatments, are expected to significantly impact cancer care.
    • Advancements in molecular biology, coupled with new technologies, offer unprecedented opportunities for biological research.

    Conclusions:

    • Biological response modifiers (BRM) are poised to be a major factor in cancer treatment advancements.
    • Continued research and resource allocation are crucial for developing effective biological anticancer agents.
    • Interdisciplinary technological advancements promise more effective cancer treatments in the coming decade.